NO20091259L - Methods to enhance hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes - Google Patents

Methods to enhance hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes

Info

Publication number
NO20091259L
NO20091259L NO20091259A NO20091259A NO20091259L NO 20091259 L NO20091259 L NO 20091259L NO 20091259 A NO20091259 A NO 20091259A NO 20091259 A NO20091259 A NO 20091259A NO 20091259 L NO20091259 L NO 20091259L
Authority
NO
Norway
Prior art keywords
treatment
methods
sodium channel
osmolytes
channel blockers
Prior art date
Application number
NO20091259A
Other languages
Norwegian (no)
Inventor
Michael R Johnson
Richard C Boucher
Andrew J Hirsch
Original Assignee
Parion Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2007/077880 external-priority patent/WO2008031028A2/en
Application filed by Parion Sciences Inc filed Critical Parion Sciences Inc
Publication of NO20091259L publication Critical patent/NO20091259L/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Det beskrives metoder og preparater for behandling av sykdommer som lindres ved øket mukociliær klaring og mukosal hydratisering ved administrering av en effektiv mengde natrium kanalblokker som angitt her og en osmolytt, til et individ som trenger øket mukociliær klaring og mukosal hydratisering.Methods and preparations for the treatment of diseases which are alleviated by increased mucociliary clearance and mucosal hydration are described by administering an effective amount of sodium channel blocks as indicated herein and an osmolyte, to a subject in need of increased mucociliary clearance and mucosal hydration.

NO20091259A 2006-09-07 2009-03-26 Methods to enhance hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes NO20091259L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84266906P 2006-09-07 2006-09-07
US84517206P 2006-09-18 2006-09-18
PCT/US2007/077880 WO2008031028A2 (en) 2006-09-07 2007-09-07 Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes

Publications (1)

Publication Number Publication Date
NO20091259L true NO20091259L (en) 2009-04-17

Family

ID=40786777

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091259A NO20091259L (en) 2006-09-07 2009-03-26 Methods to enhance hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes

Country Status (1)

Country Link
NO (1) NO20091259L (en)

Similar Documents

Publication Publication Date Title
MX2009002602A (en) Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes.
WO2008031048A3 (en) Enhanced mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
NO20170633A1 (en) Compounds of indolamine-2,3-dioxygenase for use in the treatment of cancer in combination with an anti-PD-1 antibody.
EA201000559A1 (en) COMPOSITIONS AND METHODS OF APPLICATION OF ANTIBODIES TO SKLEROSTIN
AR076941A1 (en) BACILLUS CEPA FOR A GREATER PROTEIN PRODUCTION
PA8852901A1 (en) PROTEIN CINASE INHIBITORS
PH12015502275B1 (en) Therapuetic uses of empagliflozin
EA201100302A1 (en) TREATMENT OF DIABETES IN PATIENTS FOR WHICH TREATMENT BY METFORMIN IS IMPOSSIBLE
CR10347A (en) ANTIBODIES AGAINST PEPTIDOB-AMILOID
MX349027B (en) Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy.
UY31789A1 (en) SUPER FAST PERFORMANCE INSULIN COMPOSITIONS
BR112015022096A2 (en) sodium channel modulators for pain treatment
PA8772101A1 (en) IMIDAZOL-TRIAZOLOPIRIMIDINAS REPLACED
EA201001639A1 (en) COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND APPLICATION
CL2009000402A1 (en) Substituted 2-amino-acetamide derived compounds; pharmaceutical composition; Useful in the treatment of lung diseases, rheumatic disease, autoimmune disease, among others.
MX2015013939A (en) Therapeutic uses of empagliflozin.
BR112014004726A2 (en) pharmaceutical combination for use in glycemic control in type 2 diabetes patients
CY1114792T1 (en) CLOSED TOXINS FOR USE IN EARLY EFFECTIVE TREATMENT
BR112014007675A2 (en) degenerative joint disease treatment
BR112015008418A2 (en) use of an immunogenic composition, immunogenic composition, and methods for enhancing antibody-mediated opsonic activity against a targeted streptococcus pneumoniae serotype in an individual and for immunizing a human host against diseases caused by streptococcus pneumoniae infection
EA201171339A1 (en) THE WAY TO REDUCE THE INTRA-GL PRESSURE IN PEOPLE
CR20110552A (en) TREATMENT OF INSULIN RESISTANT DISORDERS
EA201690323A1 (en) METHODS OF TREATING EAR DISEASES IN CHILDREN
BR112013030068A2 (en) water dispersible stabilized biological control granules
BRPI0821467B8 (en) recombinant furin composition, method of producing the recombinant furin composition, and, method of producing a mature protein using the recombinant furin composition

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application